Ambrisentan and Nelfinavir Mesylate
Determining the interaction of Ambrisentan and Nelfinavir Mesylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Based on in vitro data, coadministration with potent inhibitors of CYP450 3A4 and/or 2C19 may be expected to increase the plasma concentrations of ambrisentan, which is a substrate of these isoenzymes. However, administration with ketoconazole (potent CYP450 3A4 inhibitor) or omeprazole (potent CYP450 2C19 inhibitor) did not result in clinically relevant changes in ambrisentan exposure.
- "Product Information. Letairis (ambrisentan)." Gilead Sciences, Foster City, CA.
Generic Name: nelfinavir
Brand name: Viracept
Synonyms: Nelfinavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ambrisentan-Nelfinavir Oral Powder
- Ambrisentan-Nelfinavir Tablets
- Ambrisentan-Nembutal
- Ambrisentan-Nembutal Sodium injection
- Ambrisentan-Neo DM
- Ambrisentan-Neo-Fradin
- Nelfinavir Mesylate-Ambrisentan Tablets
- Nelfinavir Mesylate-Amcinonide
- Nelfinavir Mesylate-Amcinonide Cream and Ointment
- Nelfinavir Mesylate-Amcinonide Lotion
- Nelfinavir Mesylate-Amcinonide Ointment
- Nelfinavir Mesylate-Amcinonide topical